Back

Notification report


Full notification file


General information

Notification Number
B/FR/15/GT01

Member State to which the notification was sent
France

Date of acknowledgement from the Member State Competent Authority
31/12/2014

Title of the Project
A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab ompared to Ipilimumab Alone in Subjects With Previously Untreated, Unresected, Stage IIIb-IV Melanoma

Proposed period of release:
01/01/2014 to 31/01/2016

Name of the Institute(s) or Company(ies)
Amgen Limited, UK, On behalf of Amgen Inc. (study sponsor);


3. Is the same GMO release planned elsewhere in the Community?
Yes:
France;

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Genus: Simplexvirus

Species: Talimogene laherparepvec is a recombinant of a wild type Herpes simplex virus 1 (HSV-1) strain JS1, with genes ICP34.5 and ICP47 deleted and hGM-CSF inserted


Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
HSV-1SimplexvirusHerpes simplex virusJS1 (ECACC Accession Number 01010209)

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known